JP2005523318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523318A5 JP2005523318A5 JP2003585745A JP2003585745A JP2005523318A5 JP 2005523318 A5 JP2005523318 A5 JP 2005523318A5 JP 2003585745 A JP2003585745 A JP 2003585745A JP 2003585745 A JP2003585745 A JP 2003585745A JP 2005523318 A5 JP2005523318 A5 JP 2005523318A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- viruses
- treatment
- antigen
- antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 description 12
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200590 | 2002-04-19 | ||
| DKPA200200590 | 2002-04-19 | ||
| PCT/EP2003/003994 WO2003088994A2 (en) | 2002-04-19 | 2003-04-16 | Modified vaccinia virus ankara for the vaccination of neonates |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010028940A Division JP2010120955A (ja) | 2002-04-19 | 2010-02-12 | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
| JP2011115564A Division JP5690214B2 (ja) | 2002-04-19 | 2011-05-24 | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005523318A JP2005523318A (ja) | 2005-08-04 |
| JP2005523318A5 true JP2005523318A5 (enExample) | 2006-06-08 |
| JP4801880B2 JP4801880B2 (ja) | 2011-10-26 |
Family
ID=29225556
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585745A Expired - Lifetime JP4801880B2 (ja) | 2002-04-19 | 2003-04-16 | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
| JP2010028940A Pending JP2010120955A (ja) | 2002-04-19 | 2010-02-12 | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
| JP2011115564A Expired - Lifetime JP5690214B2 (ja) | 2002-04-19 | 2011-05-24 | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
| JP2014257263A Pending JP2015061876A (ja) | 2002-04-19 | 2014-12-19 | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010028940A Pending JP2010120955A (ja) | 2002-04-19 | 2010-02-12 | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
| JP2011115564A Expired - Lifetime JP5690214B2 (ja) | 2002-04-19 | 2011-05-24 | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
| JP2014257263A Pending JP2015061876A (ja) | 2002-04-19 | 2014-12-19 | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US7897156B2 (enExample) |
| EP (4) | EP1420822B2 (enExample) |
| JP (4) | JP4801880B2 (enExample) |
| KR (2) | KR20110017904A (enExample) |
| CN (1) | CN100540051C (enExample) |
| AT (1) | ATE366586T2 (enExample) |
| AU (1) | AU2003239805B2 (enExample) |
| BR (1) | BR0309339A (enExample) |
| CA (1) | CA2478009C (enExample) |
| CY (1) | CY1106848T1 (enExample) |
| DE (1) | DE60314823T3 (enExample) |
| DK (1) | DK1420822T4 (enExample) |
| EA (1) | EA011233B1 (enExample) |
| ES (1) | ES2288609T5 (enExample) |
| IL (1) | IL163701A0 (enExample) |
| MX (1) | MXPA04010353A (enExample) |
| NO (1) | NO336348B1 (enExample) |
| NZ (2) | NZ547776A (enExample) |
| PL (1) | PL220781B1 (enExample) |
| PT (1) | PT1420822E (enExample) |
| SG (1) | SG173216A1 (enExample) |
| UA (1) | UA85371C2 (enExample) |
| WO (1) | WO2003088994A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230198B1 (hu) * | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| EP1420822B2 (en) * | 2002-04-19 | 2017-07-05 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| AU2003294248A1 (en) * | 2002-11-07 | 2004-06-03 | Aventis Pasteur, Inc. | Smallpox vaccine regimen |
| CN101128217B (zh) * | 2005-02-23 | 2012-04-25 | 巴法里安诺迪克有限公司 | 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途 |
| EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
| US8268327B2 (en) * | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| US20110052627A1 (en) * | 2008-06-20 | 2011-03-03 | Paul Chaplin | Recombinant modified vaccinia virus measles vaccine |
| US8883168B2 (en) | 2010-11-05 | 2014-11-11 | Bavarian Nordic A/S | Modulation of immune responses by the poxviral K4 protein |
| WO2012122629A1 (en) | 2011-03-11 | 2012-09-20 | Mcmaster University | A method of vaccination comprising a histone deacetylase inhibitor |
| EP2892549A1 (en) * | 2012-09-04 | 2015-07-15 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| EA034825B1 (ru) | 2013-03-15 | 2020-03-25 | Бавариан Нордик А/С | Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| UA113442C2 (xx) | 2015-01-27 | 2017-01-25 | Ентеросорбент | |
| EP4122492A1 (en) * | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| JP6913032B2 (ja) | 2015-05-20 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 共通ネオ抗原 |
| TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2023118508A1 (en) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
| US12531162B1 (en) * | 2023-05-31 | 2026-01-20 | Northeastern University | Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net |
| US12562256B2 (en) * | 2023-11-07 | 2026-02-24 | New York University | Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| FR3171450A1 (fr) | 2025-01-17 | 2026-07-24 | Odimma Therapeutics | Virus enveloppé pour la transfection d’acides nucléiques exogènes. |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3914408A (en) * | 1973-10-12 | 1975-10-21 | Univ Nebraska | Vaccine for neonatal calf diarrhea |
| DE2714665A1 (de) | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| JPS6035647A (ja) † | 1983-08-09 | 1985-02-23 | Nippon Denso Co Ltd | アンチスキツド制御装置 |
| US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
| US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
| US5403582A (en) | 1993-01-21 | 1995-04-04 | Nippon Zeon Co., Ltd. | Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus |
| US5405772A (en) | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
| US6190655B1 (en) | 1993-12-03 | 2001-02-20 | Immunex Corporation | Methods of using Flt-3 ligand for exogenous gene transfer |
| DE4405841C1 (de) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ES2243937T3 (es) | 1994-04-29 | 2005-12-01 | Baxter Healthcare S.A. | Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños. |
| US5753489A (en) | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
| US5756341A (en) | 1994-11-10 | 1998-05-26 | Immuno Ag | Method for controlling the infectivity of viruses |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| AP964A (en) | 1996-02-21 | 2001-05-11 | Julianna Lisziewicz | Methods and compositions for protective and therapeutic genetic immunisation. |
| ID19548A (id) * | 1996-09-24 | 1998-07-23 | Bavarian Nordic Res Inst As | Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin |
| WO1998017283A1 (en) * | 1996-10-25 | 1998-04-30 | The Wistar Institute Of Anatomy & Biology | Method of vaccinating infants against infections |
| US6204250B1 (en) | 1996-11-22 | 2001-03-20 | The Mount Sinai Medical Center Of The City Of New York | Immunization of infants |
| GB0023203D0 (en) * | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| WO1999007869A1 (en) | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
| EP2042598A1 (en) | 1998-11-18 | 2009-04-01 | Oxford Biomedica (UK) Limited | 5T4 tumour-associated antigen for use in tumour immunotherapy |
| GB2370571B (en) | 1998-11-18 | 2003-05-07 | Oxford Biomedica Ltd | A modified 5t4 antigen |
| KR100880765B1 (ko) * | 2000-03-14 | 2009-02-02 | 버베리안 노딕 에이/에스 | 변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주 |
| JP2003533989A (ja) | 2000-05-24 | 2003-11-18 | メリアル | ブタ生殖・呼吸症候群ウィルス（ｐｒｒｓｖ）の組換えポックスウィルスワクチン |
| AU6845201A (en) * | 2000-06-15 | 2001-12-24 | Us Gov Health & Human Serv | A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses |
| EP1303286B1 (de) | 2000-07-11 | 2006-04-26 | Bayer HealthCare AG | Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs |
| DE10042598A1 (de) * | 2000-08-30 | 2002-03-28 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| HU230198B1 (hu) * | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| US20040091995A1 (en) * | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| EP1456230A2 (en) * | 2001-12-04 | 2004-09-15 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| EP1420822B2 (en) * | 2002-04-19 | 2017-07-05 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| UA82479C2 (uk) * | 2002-05-16 | 2008-04-25 | Бавариан Нордика А/С | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
| WO2005026646A2 (en) * | 2003-09-10 | 2005-03-24 | Ra Brands, L.L.C. | Process for imprinting a composite ventilated rib |
| ES2476990T3 (es) * | 2003-11-12 | 2014-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sistema para tratar y prevenir cáncer de mama |
| US7618980B2 (en) | 2004-07-14 | 2009-11-17 | Bristol-Myers Squibb Company | Pyrrolo(oxo)quinolines as 5HT ligands |
| EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
| EP1925318A1 (en) | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
| US8613936B2 (en) * | 2009-03-13 | 2013-12-24 | Bavarian Nordic A/S | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
-
2003
- 2003-04-16 EP EP03732280.7A patent/EP1420822B2/en not_active Expired - Lifetime
- 2003-04-16 KR KR1020117000242A patent/KR20110017904A/ko not_active Ceased
- 2003-04-16 UA UA20041008381A patent/UA85371C2/ru unknown
- 2003-04-16 DK DK03732280.7T patent/DK1420822T4/en active
- 2003-04-16 PT PT03732280T patent/PT1420822E/pt unknown
- 2003-04-16 AT AT03732280T patent/ATE366586T2/de active
- 2003-04-16 IL IL16370103A patent/IL163701A0/xx unknown
- 2003-04-16 WO PCT/EP2003/003994 patent/WO2003088994A2/en not_active Ceased
- 2003-04-16 BR BR0309339-5A patent/BR0309339A/pt not_active Application Discontinuation
- 2003-04-16 SG SG2007001563A patent/SG173216A1/en unknown
- 2003-04-16 EP EP10158052A patent/EP2204179A3/en not_active Withdrawn
- 2003-04-16 PL PL371594A patent/PL220781B1/pl unknown
- 2003-04-16 KR KR1020047015645A patent/KR101028937B1/ko not_active Expired - Lifetime
- 2003-04-16 JP JP2003585745A patent/JP4801880B2/ja not_active Expired - Lifetime
- 2003-04-16 DE DE60314823.9T patent/DE60314823T3/de not_active Expired - Lifetime
- 2003-04-16 EP EP07013067A patent/EP1839672A3/en not_active Withdrawn
- 2003-04-16 CA CA2478009A patent/CA2478009C/en not_active Expired - Lifetime
- 2003-04-16 EP EP10158054A patent/EP2204180A3/en not_active Withdrawn
- 2003-04-16 AU AU2003239805A patent/AU2003239805B2/en not_active Expired
- 2003-04-16 EA EA200401405A patent/EA011233B1/ru not_active IP Right Cessation
- 2003-04-16 NZ NZ547776A patent/NZ547776A/xx not_active IP Right Cessation
- 2003-04-16 ES ES03732280.7T patent/ES2288609T5/es not_active Expired - Lifetime
- 2003-04-16 MX MXPA04010353A patent/MXPA04010353A/es active IP Right Grant
- 2003-04-16 NZ NZ536592A patent/NZ536592A/en not_active IP Right Cessation
- 2003-04-16 CN CNB038087863A patent/CN100540051C/zh not_active Expired - Lifetime
-
2004
- 2004-11-12 NO NO20044941A patent/NO336348B1/no not_active IP Right Cessation
-
2007
- 2007-09-07 CY CY20071101154T patent/CY1106848T1/el unknown
-
2008
- 2008-05-12 US US12/118,841 patent/US7897156B2/en not_active Expired - Fee Related
-
2010
- 2010-02-12 JP JP2010028940A patent/JP2010120955A/ja active Pending
-
2011
- 2011-01-19 US US13/009,636 patent/US8163293B2/en not_active Expired - Fee Related
- 2011-05-24 JP JP2011115564A patent/JP5690214B2/ja not_active Expired - Lifetime
-
2012
- 2012-03-16 US US13/422,028 patent/US20120183574A1/en not_active Abandoned
-
2014
- 2014-12-19 JP JP2014257263A patent/JP2015061876A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533772A5 (enExample) | ||
| US9707285B2 (en) | Vaccination methods | |
| JP2016513115A5 (enExample) | ||
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| EP2391383B1 (en) | Codon-optimized hepatitis b virus core antigen (hbcag) | |
| MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
| EP1270016A4 (en) | VACCINE AGAINST AIDS VIRUS CONTAINING A VECTOR OF SENDAI VIRUS | |
| JP2015533841A5 (enExample) | ||
| RU2019107976A (ru) | Композиция вакцины | |
| JP2012525410A5 (enExample) | ||
| WO2000061737A3 (en) | Production of attenuated negative stranded RNA virus vaccines | |
| WO2003046506A3 (en) | Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies | |
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| WO2014063601A1 (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| Saeedi et al. | Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice | |
| Helmold et al. | Advancing ORFV‐Based Therapeutics to the Clinical Stage | |
| CN1665921A (zh) | 用于免疫治疗的腺病毒载体 | |
| CN106421774A (zh) | PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途 | |
| JP2009501012A5 (enExample) | ||
| CN106928372A (zh) | 乙肝重组抗原及其表达基因、构建方法、病毒样颗粒及其制备方法、应用与疫苗 | |
| CN1723285A (zh) | 重组的mva及其产生方法 | |
| CN102000330B (zh) | 一种核酸疫苗佐剂及其构建方法 | |
| WO2006038742A1 (ja) | 組み換えウイルスおよびその用途 | |
| CN101220373A (zh) | 一种重组病毒载体及其应用 | |
| JP2011088864A (ja) | インフルエンザウイルスに対するベクターワクチン |